Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 1.00 |
| ▸ | CDK1 | P06493 | 13/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 11/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 5/20 | 1.00 |
| ▸ | CDK7 | P50613 | 5/20 | 1.00 |
| ▸ | CDK9 | P50750 | 5/20 | 1.00 |
| ▸ | CCNH | P51946 | 5/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 4/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 13/20 | 0.68 |
| ▸ | CCNA1 | P78396 | 11/20 | 0.68 |
| ▸ | CCNB2 | O95067 | 7/20 | 0.68 |
| ▸ | CCNB3 | Q8WWL7 | 7/20 | 0.68 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.68 |
| ▸ | CDK4 | P11802 | 1/20 | 0.68 |
| ▸ | CCND1 | P24385 | 1/20 | 0.68 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.68 |
| ▸ | GSK3B | P49841 | 1/20 | 0.68 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.68 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.68 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4270801 | 0.86 | CDK2 (0.75) | CDK2CDK1CCNB1CCNT1CDK7 | |
| SCHEMBL4260619 | 0.85 | CDK2 (0.73) | CDK2CDK1CCNB1CCNT1CDK7 | |
| SCHEMBL12589612 | 0.82 | CDK2 (0.75) | CDK2CDK1CCNB1CCNT1CDK7 | |
| SCHEMBL30123470 | 0.81 | CDK2 (1.00) | CDK2CDK1CCNB1CCNT1CDK7 | |
| SCHEMBL2170816 | 0.81 | CDK2 (1.00) | CDK2CDK1CCNB1CCNT1CDK7 | |
| SCHEMBL6798577 | 0.80 | CDK2 (0.73) | CDK2CDK1CCNB1CCNT1CDK7 | |
| SCHEMBL4262481 | 0.80 | CDK2 (0.66) | CDK2CDK1CCNB1CCNT1CDK7 | |
| SCHEMBL4264564 | 0.79 | CDK2 (0.66) | CDK2CDK1CCNB1CCNT1CDK7 | |
| SCHEMBL24477949 | 0.78 | CDK2 (0.66) | CDK2CDK1CCNB1CCNT1CDK7 | |
| SCHEMBL24477842 | 0.77 | CDK2 (0.64) | CDK2CDK1CCNB1CCNT1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314234-B2 | Bicyclic pyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-11-20 | — | — | US | claimed |
| US-20090076037-A1 | BICYCLIC PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | claimed |
| WO-2008039359-A2 | BICYCLIC PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-03 | — | — | WO | claimed |
| US-8314234-B2 | Bicyclic pyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-11-20 | — | — | US | disclosed |
| US-8314234-B2 | Bicyclic pyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-11-20 | — | — | US | disclosed |
| US-8314234-B2 | Bicyclic pyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-11-20 | — | — | US | disclosed |
| US-20090076037-A1 | BICYCLIC PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076037-A1 | BICYCLIC PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076037-A1 | BICYCLIC PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | disclosed |
| WO-2008039359-A2 | BICYCLIC PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008039359-A2 | BICYCLIC PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076037-A1 | BICYCLIC PYRIMIDINE KINASE INHIBITORS | DCK, CDK2, DTYMK | CDK2 2/4885CDK1 8/4885CCNB1 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.